Vapendavir

Drug Profile

Vapendavir

Alternative Names: BTA-798

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Biota Holdings
  • Developer Aviragen Therapeutics; Biota Pharmaceuticals
  • Class Antivirals; Benzoxazoles; Small molecules
  • Mechanism of Action Rhinovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rhinovirus infections

Most Recent Events

  • 13 Feb 2017 Top-line efficacy data from phase IIb SPIRITUS trial in Rhinovirus infections released by Aviragen Therapeutics
  • 25 Jan 2017 Aviragen Therapeutics plans a phase II trial in Rhinovirus infections (NCT03024177)
  • 01 Dec 2016 Aviragen Therapeutics completes the phase IIb SPRITUS trial in Rhinovirus infections in USA, Bulgaria, Czech Republic, Georgia, Poland and Romania (NCT02367313)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top